0000000000125453

AUTHOR

Marco Gallo

0000-0001-7166-0848

showing 11 related works from this author

Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia …

2020

The growing insights in the next-generation immunotherapy and the state-of-the-art advancement in targeted-agents significantly improved clinical outcome of cancer patients by pointing towards a unexplored Achilles' heel. Novel toxicity profiles have been uncovered, representing unmet medical needs. Thus, a panel of expert provide comprehensive pharmacological and clinical evidence, to provide a patient-tailored approach to metabolic adverse events associated with novel anti-cancer treatments. Prompted by the need of a multidisciplinary cooperation, a working group of Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD) and Societa Italiana Farmacologia (SIF)…

diabetes; dyslipidemia; hypercholesterolemia; hyperglycemia; hypertriglyceridemia; immunotherapy; metabolic effect; targeted therapy; Consensus; Humans; Immunologic Factors; Italy; Medical Oncology; Neoplasms; Physicians0301 basic medicinemedicine.medical_specialtyConsensusSettore MED/06 - Oncologia MedicaImmune checkpoint inhibitorsmedicine.medical_treatmentPatient riskhypertriglyceridemiaMedical OncologyTargeted therapy03 medical and health sciences0302 clinical medicineMultidisciplinary approachNeoplasmsPhysiciansmedicineHumansImmunologic FactorsIntensive care medicineAdverse effectdiabeteshypercholesterolemiabusiness.industrydyslipidemiametabolic effectHematologytargeted therapy030104 developmental biologyOncologyItalyClinical evidence030220 oncology & carcinogenesisMetabolic effectsPosition paperhyperglycemiaimmunotherapybusiness
researchProduct

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

2017

urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies…

0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)…

2021

Pancreatic cancer (PC) is a common cause of cancer-related death, due to difficulties in detecting early-stage disease, to its aggressive behaviour, and to poor response to systemic therapy. Therefore, developing strategies for early diagnosis of resectable PC is critical for improving survival. Diabetes mellitus is another major public health problem worldwide. Furthermore, diabetes can represent both a risk factor and a consequence of PC: nowadays, the relationship between these two diseases is considered a high priority for research. New-onset diabetes can be an early manifestation of PC, especially in a thin adult without a family history of diabetes. However, even if targeted screening…

Cancer Researchmedicine.medical_specialtyConsensusReviewDiseaseMedical OncologySystemic therapyNOconsensus; diabetes; early diagnosis; hyperglycaemia; pancreatic carcinoma; Consensus; Humans; Medical Oncology; Diabetes Mellitus; Pancreatic Neoplasms; PhysiciansDiabetes mellitusPancreatic cancerPhysiciansmedicineDiabetes MellitusHumansFamily historyRisk factorLS4_3Intensive care medicinediabetes pancreatic carcinoma early diagnosis consensus hyperglycaemiadiabetespancreatic carcinomabusiness.industryPublic healthmedicine.diseasePancreatic NeoplasmsOncologyPosition paperbusinesshyperglycaemiaearly diagnosis
researchProduct

Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of …

2022

Corticosteroids (CSs) are widely used in oncology, presenting several different indications. They are useful for induction of apoptosis in hematological neoplasms, for management of anaphylaxis and cytokine release/hypersensitivity reaction and for the symptomatic treatment of many tumour- and treatment-related complications. If the employment of CSs in the oncological setting results in several benefits for patients and satisfaction for clinicians, on the other hand, many potential adverse events (AEs), both during treatment and after withdrawal of CSs, as well as the duality of the effects of these compounds in oncology, recommend being cautious in clinical practice. To date, several gray…

ConsensusSurvivalTumour responseSettore MED/06 - Oncologia MedicaContraindicationsHematologyMedical OncologyItalyOncologyAdrenal Cortex HormonesDoseAdverse eventsHumansCorticosteroidsIndicationsGlucocorticoidsSocieties MedicalCancer
researchProduct

Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical …

2022

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of malignancies derived from neuroendocrine cells that can occur anywhere along the gastrointestinal tract. GEP-NETs incidence has been steadily increasing over the past decades, in parallel with the increasing incidence of the metabolic syndrome (MetS). It is not yet fully known whether the MetS components (such as obesity, dyslipidemia and type 2 diabetes) could be involved in the etiology of GEP-NETs or could influence their outcomes. In this review, a panel of experts of the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Endocrinology…

ConsensusSettore MED/06 - Oncologia MedicaGEP-NET progressionMetabolic disordersHematologyMedical OncologyMetabolic syndromeNOGEP-NET survivalPancreatic NeoplasmsNeuroendocrine Tumorsgastroenteropancreatic neuroendocrine tumors; gep-net progression; gep-net survival; metabolic disorders; metabolic syndrome; consensus; humans; medical oncology; diabetes mellitus; type 2; intestinal neoplasms; neuroendocrine tumors; pancreatic neoplasms; stomach neoplasmsOncologyGEP-NET progression; GEP-NET survival; Gastroenteropancreatic neuroendocrine tumors; Metabolic disorders; Metabolic syndromeDiabetes Mellitus Type 2Stomach NeoplasmsIntestinal NeoplasmsDiabetes MellitusHumansLS4_3Gastroenteropancreatic neuroendocrine tumorsType 2
researchProduct

Clinical profiles and quality of care of adults with type 1 diabetes according to their cardiovascular Risk: A Multicenter, Observational, retrospect…

2021

Abstract Aims The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 1 diabetes (T1D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD (Associazione Medici Diabetologi) Annals initiative. Patients with T1D were stratified by cardiovascular risk. Measures of intermediate outcomes, intensity/appropriateness of pharmacological treatment, and over…

Type 1 diabetesmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismMedical recordRetrospective cohort studyGeneral Medicinemedicine.diseasePharmacological treatmentEndocrinologyRisk groupsDiabetes Mellitus Type 1Cardiovascular DiseasesHeart Disease Risk FactorsRisk FactorsDiabetes mellitusEmergency medicineInternal MedicinemedicineHumansObservational studyQuality of carebusinessRetrospective StudiesDiabetes research and clinical practice
researchProduct

Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)…

2021

Most anticancer molecules are administered in body-size-based dosing schedules, bringing up unsolved issues regarding pharmacokinetic data in heavy patients. The worldwide spread of obesity has not been matched by improved methods and strategies for tailored drug dosage in this population. The weight or body surface area (BSA)-based approaches may fail to fully reflect the complexity of the anthropometric features besides obesity in cancer patients suffering from sarcopenia. Likewise, there is a lack of pharmacokinetic data on obese patients for the majority of chemotherapeutic agents as well as for new target drugs and immunotherapy. Therefore, although the available findings point to the …

obesityCancer Researchmedicine.medical_specialtypharmacokinetic parametersConsensusBSAcancer drug dosingPopulationchemotherapy doseAntineoplastic AgentsReviewOverweightNODosing schedulesNeoplasmsPhysiciansInternal medicineHumansMedicineDosingLS4_3educationBody surface areaeducation.field_of_studybusiness.industryCancerCytotoxic chemotherapymedicine.diseaseOncologyBSA; cancer drug dosing; chemotherapy dose; obesity; pharmacokinetic parametersPosition paperBSA; cancer drug dosing; chemotherapy dose; obesity; pharmacokinetic parameters; Consensus; Humans; Obesity; Antineoplastic Agents; Neoplasms; Physiciansmedicine.symptombusinessESMO Open
researchProduct

The treatment of hyperinsulinemic hypoglycaemia in adults: an update

2016

Treatment of hyperinsulinemic hypoglycaemia (HH) is challenging due to the rarity of this condition and the difficulty of differential diagnosis. The aim of this article is to give an overview of the recent literature on the management of adult HH. A search for reviews, original articles, original case reports between 1995 and 2016 in PubMed using the following keywords: hyperinsulinemic hypoglycaemia, insulinoma, nesidioblastosis, gastric bypass, autoimmune hypoglycaemia, hyperinsulinism, treatment was performed. One hundred and forty articles were selected and analysed focusing on the most recent treatments of HH. New approaches to treatment of HH are available including mini-invasive sur…

Adultmedicine.medical_specialtyPediatricsendocrine system diseasesEndocrinology Diabetes and MetabolismGastric bypassNesidioblastosis030209 endocrinology & metabolismHypoglycemiaSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyHyperinsulinismmedicineHyperinsulinemic hypoglycaemiaHumansAutoimmune hypoglycaemiaInsulinomaEverolimusbusiness.industryAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Adult; Humans; Hyperinsulinism; HypoglycemiaAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Adult; Humans; Hyperinsulinism; Hypoglycemia; Endocrinology Diabetes and Metabolism; EndocrinologySettore MED/13 - ENDOCRINOLOGIANesidioblastosimedicine.diseaseHypoglycemiaSurgeryDiabetes and MetabolismTreatmentNesidioblastosisAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment030220 oncology & carcinogenesisAutoimmune hypoglycaemiaInsulinomaAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Endocrinology Diabetes and Metabolism; EndocrinologyDifferential diagnosisbusinessHyperinsulinismhormones hormone substitutes and hormone antagonistsmedicine.drugHuman
researchProduct

An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience

2020

Diabetes and cancer frequently coexist in the same subject, often with relevant clinical effects on the management and prognosis of the comorbid patient. The existing guidelines, however, do not appropriately address many clinical issues in this setting. Although collaboration between diabetologists and oncologists should play an important role in achieving appropriate levels of care, close coordination or agreement between these specialists is seldom offered. There is an urgent need for greater interdisciplinary integration between all specialists involved in this setting, for a shared approach ensuring that organisational silos are overcome. To this end, the Italian Associations of Medica…

Glucose controlHospital settingSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismMedical OncologyDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyClinical pathwayClinical pathwaysClinical pathwayDiabetes mellitusNeoplasmsInternal MedicineMedicineHumans030212 general & internal medicineInpatient diabetes careDiabetes and cancerbusiness.industryDelivery of Health Care IntegratedCancerGeneral MedicineInpatient hyperglycaemiamedicine.diseasePrognosisIntegrated careItalyOncologyDischarge planningContinuity of careMedical emergencybusiness
researchProduct

From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

2020

AbstractGut microbiota is represented by different microorganisms that colonize the intestinal tract, mostly the large intestine, such as bacteria, fungi, archaea and viruses. The gut microbial balance has a key role in several functions. It modulates the host’s metabolism, maintains the gut barrier integrity, participates in the xenobiotics and drug metabolism, and acts as protection against gastro-intestinal pathogens through the host’s immune system modulation. The impaired gut microbiota, called dysbiosis, may be the result of an imbalance in this equilibrium and is linked with different diseases, including cancer. While most of the studies have focused on the association between microb…

Endocrinology Diabetes and MetabolismTumor microenvironment.BiologyGut floraNeuroendocrine tumorsmedicine.disease_causedigestive systemArticle03 medical and health sciences0302 clinical medicineEndocrinologyImmune systemNeuroendocrine tumorGastro-medicineHumansCytokine030304 developmental biologyGastrointestinal NeoplasmsInflammation0303 health sciencesTumor microenvironmentMicrobiotadigestive oral and skin physiologymedicine.diseasebiology.organism_classificationCytokines; Inflammation; Microbiota; Neuroendocrine tumors; Tumor microenvironmentGastrointestinal MicrobiomeTumor microenvironment030220 oncology & carcinogenesisImmunologyDysbiosisCytokinesNeuroendocrine tumorsCarcinogenesisDysbiosisDrug metabolism
researchProduct

Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, inten…

AdultBlood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismType 2 diabetesIncretinsRisk AssessmentDiabetes mellitusInternal medicinemedicineElectronic Health RecordsHumansHypoglycemic AgentsMedical prescriptionSodium-Glucose Transporter 2 InhibitorsOriginal InvestigationAgedQuality Indicators Health CareRetrospective StudiesAngiologyCardiovascular risk Humans Hypoglycemic Agents Incretins Italy Male Middle Aged Retrospective Studies Risk Assessment Sodium-Glucose Transporter 2 Inhibitors Time Factors Treatment Outcome Quality Indicators Health Care Quality of care Type 2 diabetes Adult Aged Aged 80 and over Biomarkers Blood Glucose Cardiovascular Diseases Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Heart Disease Risk Factors Female Electronic Health RecordsAged 80 and overDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMedical recordQuality of careType 2 diabetesRetrospective cohort studyMiddle AgedCardiovascular riskmedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2ItalyCardiovascular DiseasesHeart Disease Risk Factorslcsh:RC666-701AlbuminuriaFemaleObservational studymedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct